The QualityStocks Daily Tuesday, June 21st, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(CNVY) $10.3000 +138.43%

QualityStocks(REV) $6.0600 +62.47%

Tiny Gems(GBOX) $1.5000 +36.36%

The QualityStocks Daily Stock List

Neptune Wellness Solutions (NEPT)

Ceocast News, The Howard Group, StockMarketWatch, MarketBeat, MarketClub Analysis, Schaeffer's, TraderPower, StreetInsider, StockRockandRoll, PennyStockLocks, QualityStocks, SmallCapVoice, BUYINS.NET, CFN Media Group, Market Intelligence Center Alert, Penny Stock 101, Wealth Insider Alert, The Street, InvestmentHouse, Street Insider, Cabot Wealth, INO Market Report, Investor Development Group, InvestorPlace, Market Intelligence Center, PennyTrader Publisher, TradersPro, Penny Stock 113, Penny Stock 119, The Weekly Options Trader, Beacon Equity Research, Zacks, Streetwise Reports, Stock Preacher, Stock Stars, Stockhouse and Wall Street Resources reported earlier on Neptune Wellness Solutions (NEPT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSE: NEPT) (FRA: NTU) is an integrated wellness and health firm which is engaged in building a portfolio of plant-based and affordable consumer packaged products under the OCEANO3, Mood Ring, Forest Remedies, Neptune Wellness and Ocean Remedies brands.

The firm was founded in 1998 and is based in Laval, Canada. Neptune Wellness has a partnership agreement with International Flavors and Fragrances Inc. to co-develop CBD products derived from hemp for the wellness and health markets as well as for mass retail.

Neptune Wellness Solutions provides supply chain solutions and turnkey product development services to government customers and businesses in various health and wellness markets, such as white label consumer packaged goods, nutraceuticals, hemp and legal marijuana.

Additionally, the firm offers purification and extraction services from hemp and marijuana biomass, quality control, raw material sourcing, quality assurance and quality control services. Under quality assurance, the firm primarily deals with ingredients derived from hemp and omega-3, such as liquids, capsules and soft gels.

The firm’s patented omega-3 oils delivery technology was recently found to be 3 times more absorbable than other fish oils in the market, which puts Neptune Wellness Solutions at the top of an omega-3 ingredients market that is rapidly growing, with forecast showing that the value of the market will be close to $10 billion in a few years.

Neptune Wellness Solutions (NEPT), closed Tuesday's trading session at $2.9, up 25%, on 165,265 volume. The average volume for the last 3 months is 164,026 and the stock's 52-week low/high is $2.13/$44.45.

Four Seasons Education (FEDU)

Trading Concepts, StockMarketWatch and QualityStocks reported earlier on Four Seasons Education (FEDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Four Seasons Education (Cayman) Inc. (NYSE: FEDU) is an education firm that is engaged in the provision of after-school education services with a focus on high-quality elementary school mathematics education.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in 2007 by Peiqing Tian. It operates as part of the education sector and serves consumers in China.

The company helps unlock every student’s intellectual potential through the use of education that can benefit the student’s life, career and academic prospects. Its courses are divided into kindergarten, middle school and elementary school programs.

The enterprise’s education services are made up of experimental courses for middle school English, Chinese, chemistry, physics, mathematics and other subjects; study trips to historical scenic spots and sites; interest-oriented programs which include courses delivered to K-12 learning institutions and workshops on some mathematics topics; and picture talk workshops which allow students to develop their cognitive abilities. In addition to this, it offers courses on the Chinese phonetic system, namely pinyin, which students learn when they start the formal study of Chinese. Furthermore, the enterprise also offers management and education consulting services, as well as online education services through its mobile application and website.

As of February 2021, the firm operates 50 learning centers in China. The firm is focused on promoting student engagement, increasing the number of learning centers and growing. These moves will not only help students perform better and improve their logic and cognitive abilities but will also promote investments into the firm as well as boost the company’s growth.

Four Seasons Education (FEDU), closed Tuesday's trading session at $10.38, up 20.6977%, on 217,784 volume. The average volume for the last 3 months is 217,561 and the stock's 52-week low/high is $6.41/$29.40.

Hallador Energy (HNRG)

TradersPro, Zacks, SmarTrend Newsletters, QualityStocks, Wall Street Resources, MarketClub Analysis, MarketBeat, Market Intelligence Center Alert, Trading Concepts, StreetInsider, InvestorPlace and Daily Market Beat reported earlier on Hallador Energy (HNRG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hallador Energy Company (NASDAQ: HNRG) (FRA: H7H) is a coal mining firm that is focused on the production of steam coal for the electricity and power generation industry.

The firm has its headquarters in Terre Haute, Indiana and was incorporated in 1951 by David C. Hardie. It serves consumers in the United States.

The company’s operating business segments include two Oaktown underground mines which are found in southwest Indiana, known as Oaktown 1 Mine and Oaktown 2 Mine. It sells most of its coal to big coal-fired power plants in Indiana. The company mainly operates through its Sunrise Coal subsidiary.

The enterprise’s projects include Bulldog Mine, Carlisle mine, Oaktown 1 Mine, Oaktown 2 mine and the Ace in the Hole mine which is situated roughly 40 miles northeast of the Carlisle mine. The Bulldog mine controls more than 35 tons of coal reserves.

It develops more than 10 million tons of coal every year and has more than 40 million tons of the Indiana coal Vi sea. The enterprise also has more than 69 million controlled tons in Lawrence and Indiana county and Knox county, Illinois. In addition to this, it owns a transport facility on the Ohio River dubbed the Summit Terminal.

The company recently reported its first half financial results for this year which show improvements in contracted sales as well as an increase in shipments. It is focused on expanding its portfolio to include renewable energy, which will play a big role in the company’s evolution. The move will also bring in more investors into the firm, which will have a positive influence on the company’s growth.

Hallador Energy (HNRG), closed Tuesday's trading session at $7.38, up 21.9835%, on 1,854,092 volume. The average volume for the last 3 months is 1.849M and the stock's 52-week low/high is $1.99/$7.62.

BT Brands Inc. (BTBD)

We reported earlier on BT Brands Inc. (BTBD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BT Brands Inc. (NASDAQ: BTBD) operates and owns a chain of fast food restaurants in various regions of the United States.

The firm has its headquarters in West Fargo, North Dakota and was incorporated in 1987. It operates as part of the restaurants and other eating places industry. The firm has three companies in its corporate family and serves consumers in the United States.

The enterprise operates one Dairy Queen (DQ) franchise in Ham Lake, Minnesota and 9 Burger Time restaurants. It has 2 Burger Time locations in South Dakota, 4 locations in North Dakota and 3 locations in Minnesota. The enterprise’s Dairy Queen restaurant serves food from the DQ approved menu while its Burger Time restaurants offer a variety of foods, including pulled pork sandwiches, chicken sandwiches and burgers, as well as soft drinks and side dishes. Its Burger Time restaurants provide burger favorites, which include a full pound burger, a jalapeno burger and a mushroom Swiss burger. Its variety of burgers include Bigger Burgers, which are larger in diameter than the average burger and are made with 25% more meat. The enterprise’s burgers are custom made to its supplier’s specifications, with beef as the major ingredient. Every burger is prepared according to a customer’s order.

The company recently reported its latest financial results which show an increase in total restaurant sales. The company is currently focused on pursuing its plans to grow through acquisitions in the restaurant industry, which will not only expand their consumer reach and bring in additional revenue, but also encourage more investors into the company.

BT Brands Inc. (BTBD), closed Tuesday's trading session at $2.76, up 16.4557%, on 116,718 volume. The average volume for the last 3 months is 116,718 and the stock's 52-week low/high is $1.55/$5.25.

BlackSky Technology (BKSY)

Schaeffer's, QualityStocks, Trades Of The Day and Daily Trade Alert reported earlier on BlackSky Technology (BKSY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BlackSky Technology Inc. (NYSE: BKSY) is engaged in the provision of geospatial imagery, intelligence, mission systems and associated data analytics services and products.

The firm has its headquarters in Herndon, Virginia and was incorporated in 2014. Prior to its name change, the firm was known as Osprey Technology Acquisition Corp. It operates as part of the computer systems design and related services industry. The firm serves consumers around the globe.

The company is focused on being the leading provider of real-time geospatial intelligence. It has developed a monitoring service platform known as Spectra AI, which is powered by advanced computer techniques, including natural language processing, computer vision, artificial intelligence and machine learning. The company uses the platform to harness data from various sensor networks and as well as its own satellite constellation. It then processes and combines the data elements gathered from its constellation as well as different internet-of-things, space and terrestrial-based data feeds and sensors, and uses it to monitor facilities and activities globally.

The enterprise’s platform offers mission planning, autonomous tasking, health and safety monitoring of constellation, control and command services, distribution of image and imagery derived products and automated generation. Its monitoring solution requires no IT setup or infrastructure.The enterprise’s service offerings include software and analytics and imagery data and services. It serves the environmental, climate, catastrophe, industrial construction, commercial, government intelligence and defense markets.

The firm recently added Geoimage, another geospatial solutions provider, to its reseller network. This move allows BlackSky to expand its global reseller network and extend its consumer reach into a new region, which will not only bring in significant additional revenues but also help meet the demand and needs of Geoimage’s consumers more efficiently.

BlackSky Technology (BKSY), closed Tuesday's trading session at $2.44, up 20.197%, on 55,136,258 volume. The average volume for the last 3 months is 54.568M and the stock's 52-week low/high is $1.00/$13.20.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, Money Morning, TopStockAnalysts, Daily Trade Alert, Investopedia, Louis Navellier, Zacks, VectorVest, Trading Markets,, The Growth Stock Wire, ProfitableTrading, Daily Wealth, The Wealth Report, TheStockAdvisors, StreetAlerts, All about trends, Wall Street Elite, Top Pros' Top Picks, Streetwise Reports, Leeb's Market Forecast, TradingMarkets, The Online Investor, Market FN, Market Report, Dividend Opportunities, TheStockAdvisor, InvestmentHouse, StockTwits, Investor Guide, Investors Alley, Wealth Insider Alert, Investment House, Trading Concepts, Options Trader Elite, The Best Newsletters, Money and Markets, InvestorGuide, Market Intelligence Center Alert, Energy and Capital, Wyatt Investment Research, Bourbon and Bayonets, Darwin Investing Network, Investing Signal, AnotherWinningTrade, Buttonwood Research, Trade of the Week, Wealth Daily, The Motley Fool, MarketWatch, Investor Update, Profit Confidential, QualityStocks, Market Authority, Wall Street Daily, Street Insider, Trading Tips, TradingAuthority Daily, Stock Research Newsletter, Cabot Wealth, Wealthpire Inc., Super Stock Investor, InvestorsUnderground, AllPennyStocks, CNBC Breaking News, Daily Markets, FNNO Newsletters, Uncommon Wisdom, Normandy Investment Research and 24/7 Trader reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CRU Group, a business intelligence company, believes that copper’s outlook may not be as bright as we thought, thanks to a myriad of market risks. While speaking at a mining conference in Toronto, the CRU Group director of copper research and strategy Vanessa Davidson stated that these threats could stand in the way of copper’s growth at a time when the world needed the metal to help wean itself off of fossil fuels.

During her remarks, she listed some threats, which included reduced gross domestic product (GDP), reduced industrial production caused by geopolitical upheaval, increasing rates of inflation and the economic effects of the coronavirus pandemic. In the near term, copper is threatened by copper substitutes, increasing scrap availability, decreasing rates of industrial metal use and the slow uptake of green technologies. All these risks pose a major threat to copper’s outlook.

Last week copper prices on the London Metal Exchange fell by 2.3%, and despite rising more than 25% each year for the past two years, copper has gone down 4.4% thus far. This most recent price fall was the highest-ever drop in a month and was partly caused by fears that the economy will enter a recession due to interest rate hikes by the Federal Reserve.

Davidson remains optimistic about the red metal’s long-term demand outlook however, thanks in part to expected consumption by renewable-energy technologies coupled with the electric vehicle industry. The green-energy industry is expected to increase global copper demand by an extra 2 million tons by 2030, she said. Furthermore, her company’s latest forecast shows that global demand for copper is predicted to rise by 2.1% each year until it hits 28.5 million tons in 2030.

Copper consumption by green-energy technologies is also expected to increase, she added, rising from 2% of total copper consumption in 2015 to roughly 20% by the year 2040.

In the near term, the copper market may run into some hiccups, especially if the transition from the use of fossil fuels to green energy doesn’t pick up as expected. Without the demand from green-energy technologies, Davidson noted at the Prospects & Developers Association of Canada conference, worldwide consumption of copper will level out at 25 million tons in 2027.

In March, the company’s head of base metals supply stated that by 2030, there could be an annual copper supply deficit of 4.7 million tons and that the copper industry would need to pour more than $100 billion into new copper mines to meet this supply shortfall. However, the threats outlined by Davidson may put a damper on this demand, especially from the green-energy and electric-vehicle sectors, which will cause sales to plateau.

At the moment, major extractors such as Freeport-McMoRan Inc. (NYSE: FCX) may not be overly concerned about the fluctuations on the market because the long-term outlook is a bullish one for copper.

Freeport-McMoRan Inc. (FCX), closed Tuesday's trading session at $34.03, up 0.620934%, on 13,645,044 volume. The average volume for the last 3 months is 13.331M and the stock's 52-week low/high is $30.02/$51.99.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, Schaeffer's, Kiplinger Today, QualityStocks, MarketBeat, StockMarketWatch, StreetInsider, StocksEarning, TradersPro, The Street, Trades Of The Day, Daily Trade Alert, TopPennyStockMovers, TraderPower, BUYINS.NET, Zacks, Wealth Insider Alert, Early Bird, Jason Bond, Cabot Wealth, InvestorsUnderground, PoliticsAndMyPortfolio, StockOodles, The Online Investor,, Profitable Trader Authority, Stock Beast, Wealth Daily, Energy and Capital, The Best Newsletters, Daily Market Beat and The Wealth Report reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A California-based company has unveiled a new electric vehicle battery technology that would allow EV owners to fully charge their EVs in under 10 minutes. Developed by Evonix, these battery cells are capable of charging from zero to-80% in only 5.2 minutes and up to 98% capacity in not more than 10 minutes.

Evonix’s novel battery cells were also able to retain a whopping 93% of their capacity after more than 1,000 charging cycles. These figures are unprecedented in the EV battery space and have shattered the 80% charge in 15 minutes target set by the United States Advanced Consortium (USABC) by a wide margin.

Evonix has been able to achieve this groundbreaking feat by using silicone anodes rather than the graphite anodes that are currently used in most lithium-ion batteries. Silicone anodes have been gaining popularity as an alternative battery material due to their immense energy density. On average, a silicon anode can store more than double the energy a graphite anode can hold.

Cofounder, CEO and president of Evonix Harrold Rust says fast charging has the potential to speed up mass electric vehicle adoption and that their fast-charging technology has surpassed many of the road maps set for original equipment manufacturers (OEMs). Evonix’s fast-charging batteries would grant EV owners greater range and super-fast charging speeds.

Evonix cofounder and CTO Ashok Lahiri say the silicon battery’s unique architecture allows it to fully charge in less than 10 minutes while maintaining a high life cycle. Research has shown that ordinary lithium-ion battery packs will degrade over time and even lose some of their lifespans after repeated cycles of fast charging. Evonix has been able to avoid this pitfall.

The Freemont-based company used a few tricks to work around the problems caused by silicon’s high-energy density. For starters, each battery cell is surrounded by a constraint system made of stainless steel to prevent the battery from swelling up. Orienting the electrodes to face the battery’s small side reduces the amount of constraining force needed to keep the battery from swelling.

This system of integrated stainless steel constraints provides a perpetual stack pressure that prevents particles from disconnecting electronically and cracking.

Lahiri is scheduled to make a presentation titled “Silicon-Anode Lithium-Ion Batteries for EV Applications” at the 12th International Advanced Automotive Battery Conference (AABC) Europe. His presentation will provide an overview of how Evonix’s fast-charge batteries work and an update about its electric vehicle program.

If this project proceeds according to plan, it may not be long before these new batteries find widespread use in the EVs made by manufacturers such as Workhorse Group Inc. (NASDAQ: WKHS) as more concerns of motorists are addressed.

Workhorse Group Inc. (WKHS), closed Tuesday's trading session at $2.89, off by 1.7007%, on 4,069,583 volume. The average volume for the last 3 months is 4.07M and the stock's 52-week low/high is $2.11/$18.00.

Phathom Pharmaceuticals (PHAT)

MarketBeat, StockMarketWatch, BUYINS.NET, Trades Of The Day, StreetInsider and Daily Trade Alert reported earlier on Phathom Pharmaceuticals (PHAT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is a clinical-stage biopharmaceutical firm that is engaged in the development and commercialization of treatments for gastrointestinal illnesses.

The firm has its headquarters in Florham Park, New Jersey and was incorporated in 2018, on January 9th by Roger Ulrich, Aditya Kohli, Azmi Nabulsi, David Socks and Tadataka Yamada. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers around the globe.

The company has assembled a leading team of seasoned pharmaceutical and gastrointestinal industry experts with proven experience in the development and commercialization of highly innovative therapies. It has rights in the United States, Canada and Europe to market its vonoprazan formulation.

The enterprise’s product candidates include a P-CAB (potassium-competitive acid blocker) dubbed vonoprazan, which blocks acid secretion in the stomach. This candidate is undergoing phase 3 clinical trials evaluating its effectiveness in treating erosive gastroesophageal reflux disease (GERD). Its efficacy when combined with antibiotics to treat H. pylori infections is also being tested. H. pylori (Helicobacter pylori) is a bacterial pathogen while GERD is an illness which develops when the reflux of acidic contents in the stomach causes troublesome complications and/or symptoms.

The firm recently submitted an NDA application for its vonoprazan formulation to the FDA. The success and approval of this candidate in the treatment of erosive esophagitis and heartburn will benefit patients with these indications and bring in additional revenues into the firm.

Phathom Pharmaceuticals (PHAT), closed Tuesday's trading session at $7.57, up 20.7337%, on 841,783 volume. The average volume for the last 3 months is 841,018 and the stock's 52-week low/high is $6.095/$37.17.

Innodata Inc. (INOD)

TradersPro, MarketBeat, Wall Street Resources, SmarTrend Newsletters,, Top Pros' Top Picks, Street Insider, Short Term Wealth, Market Wrap Daily, InvestorPlace, Greenbackers and FeedBlitz reported earlier on Innodata Inc. (INOD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Innodata Inc. (NASDAQ: INOD) is an international data engineering firm that is engaged in the provision of products, services and solutions that their clients use in the creation, management and distribution of digital information.

The firm has its headquarters in Ridgefield Park, New Jersey and was incorporated in 1988 by Todd H. Solomon. Prior to its name change in June 2012, the firm was known as Innodata Isogen Inc. It operates as part of the information technology services industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in Canada, the Netherlands and the United Kingdom.

The enterprise operates through the Agility, Synodex and Digital Data Solutions. The agility segment is engaged in the provision of an industry platform that offers marketing communications and PR professionals a solution to distribute content to social media influencers and journalists. The platform also monitors and analyzes international news channels like TV, radio, web and print, as well as social media channels. The Synodex segment provides an industry platform which can transform medical records into usable digital data with its client data models or proprietary data models. On the other hand, the digital solutions segment is engaged in the provision of AI-enabled software platforms and managed services to firms that need data for training machine learning and artificial intelligence algorithms. It also offers AI digital transformation solutions to help firms in problems associated with analyzing and obtaining insights from documents. In addition to this, it offers data engineering support services.

The company’s recently released financial results show significant increases in its revenues. It is currently focused on capitalizing on its large and growing market opportunity, which will create long-term value for its shareholders and bolster its growth.

Innodata Inc. (INOD), closed Tuesday's trading session at $4.83, up 2.5478%, on 37,359 volume. The average volume for the last 3 months is 37,359 and the stock's 52-week low/high is $4.32/$11.25.

Hydrofarm Holdings (HYFM)

Schaeffer's, StocksEarning, InvestorPlace, Early Bird, StreetInsider, MarketBeat and Kiplinger Today reported earlier on Hydrofarm Holdings (HYFM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hydrofarm Holdings Group Inc. (NASDAQ: HYFM) is a holding firm that is focused on manufacturing and distributing CEA (controlled environment agriculture) supplies and equipment.

The firm has its headquarters in Shoemakersville, Pennsylvania and was incorporated in 1977. It operates as part of the machinery, equipment and supplies merchant wholesalers industry, under the industrials sector. The firm has twenty-four companies in its corporate family and serves consumers in the United States.

The company operates through the Canada and the United States geographical segments. It provides its products under the GROW!T, oxyClone, Phat, Autopilot, Active Eye, Jump Start, SunBlaster, Agrobrite, Digilux, Xtrasun, Quantum, Innovative Growers Equipment, Gaia Green, Grotek, Procision, Soul, Roots Organics, Mad Farmer, House and Garden, HEAVY 16, Active Air, Active Aqua, PhotoBio and Phantom brands.

The enterprise provides plant additives, nutrients, indoor climate control equipment and agricultural lighting devices used to grow and farm marijuana, fruits, flowers, grains, vegetables, plants and herbs in controlled environments; and a range of growing media made from coconut fiber, rock wool or soil. It is also involved in the distribution of CEA supplies and equipment, which includes nutrient and fertilizer delivery systems, filters, chillers, heaters and water pumps, carbon dioxide and humidity controllers and monitors, HVAC systems, and grow light systems. It also offers hydroponics systems like hydro trays and components, hydro systems, solutions and meters, irrigation systems and pumps, containers and pots, water filtration systems, tarps and tents. This is in addition to offering atmospheric control equipment, which consists of timers, monitors and controllers as well CO2 and air purification equipment.

The firm remains focused on strengthening its business through acquisitions, as well as the expansion of its manufacturing and distribution footprint. This will position the firm for long-term growth, which will help create value for its shareholders.

Hydrofarm Holdings (HYFM), closed Tuesday's trading session at $4.26, up 5.1852%, on 971,156 volume. The average volume for the last 3 months is 971,053 and the stock's 52-week low/high is $3.88/$60.70.

Humacyte Inc. (HUMA)

MarketBeat and MarketClub Analysis reported earlier on Humacyte Inc. (HUMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Humacyte Inc. (NASDAQ: HUMA) is focused on developing and manufacturing implantable, off-the-shelf and bioengineered human tissues to help treat conditions and illnesses across various anatomic locations in a range of therapeutic areas.

The firm has its headquarters in Durham, North Carolina and was incorporated in 2004, on October 13th by Juliana L. Blum and Laura E. Niklason. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe, with a focus on consumers in the United States.

The company is focused on the development of a disruptive biotechnology platform to deliver universally bioengineered implantable human organs and tissues designed to improve the lives of patients and transform the practice of medicine.

The enterprise develops human acellular matrix products for non-vascular and vascular applications. Its investigational products can be easily implanted without causing immune rejection or inducing a foreign body response. Its acellular vessels target the vascular replacement, reconstruction and repair market, including vascular trauma, coronary artery bypass grafting, peripheral arterial disease, and arteriovenous access for hemodialysis. The enterprise is also developing its matrix products for cellular therapy delivery, including pancreatic islet cell transplantation for the treatment of type I diabetes, and pediatric heart surgery.

The firm remains focused on advancing its human tissue platform and completing late-stage clinical trials in arteriovenous access for hemodialysis and vascular trauma. The introduction of the firm’s products to the market will not only address unmet medical needs but also help create shareholder value.

Humacyte Inc. (HUMA), closed Tuesday's trading session at $3.6, off by 4%, on 760,877 volume. The average volume for the last 3 months is 760,877 and the stock's 52-week low/high is $3.50/$17.45.

Cosmos Holdings (COSM)

QualityStocks, TopPennyStockMovers, PoliticsAndMyPortfolio, OTC Markets Group, MarketBeat and Broad Street reported earlier on Cosmos Holdings (COSM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cosmos Holdings Inc. (NASDAQ: COSM) (FRA: V67) is a vertically integrated pharmaceutical firm that is engaged in the identification, acquisition, development and commercialization of genetic nutraceuticals, medical devices, over-the-counter medications and pharmaceuticals that improve patient outcomes and lives.

The firm has its headquarters in Chicago, Illinois and was incorporated in 2009, on July 21st. Prior to its name change in November 2013, the firm was known as Prime Estates and Developments Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe.

The company has an extensive network of over 150 clients and vendors in Greece, the Netherlands, Poland, Sweden, Ireland, Singapore, France, Italy, Denmark, the United Arab Emirates, the United Kingdom and Germany. It operates through its subsidiaries, selling pharmaceutical products throughout Europe on wholesale. Its subsidiaries include Cosmofarm S.A., Decahedron Ltd and SkyPharm S.A. SkyPharm is also involved in the development and sale of its own branded nutraceutical product line. The company has distribution centers and offices in Harlow, U.K. and Thessaloniki, Greece.

The enterprise’s portfolio consists of over 70 product codes including minerals, vitamins and other herbal extracts used for health care and prevention needs. It also operates a fully automated warehouse system with a single A-frame type system, a pair of ROWA type systems and a trio of robotic systems.

The company’s recently announced financial results show significant increases in its revenues. It remains focused on strengthening its balance sheet, expanding geographically and penetrating more markets in the European Union. This will bring in additional revenues while also bolstering the company’s growth.

Cosmos Holdings (COSM), closed Tuesday's trading session at $0.471, up 4.6667%, on 316,165 volume. The average volume for the last 3 months is 316,165 and the stock's 52-week low/high is $0.45/$6.21.

The QualityStocks Company Corner


The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, has announced a slate of influential industry experts that will be speakers at the Sequire Decentralized Web Conference. The event, to take place from 10:00 am ET to 6:00 pm ET on Thursday, June 23, 2022, is bringing together a list of influential companies making history in the decentralized web sector for a full day of presentations. The speakers will share insight on engaging topics such as blockchain, NFTs, web 3.0, digital currency, and more. To view the full press release, visit

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $3.36, up 2.7523%, on 55,339 volume. The average volume for the last 3 months is 55,339 and the stock's 52-week low/high is $3.00/$6.50.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions
  • Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses 
  • DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins 
  • The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective registered treatment for hypertension, while other anticipated potential therapies target seizures, nicotine addiction and erectile dysfunction

The COVID pandemic that roiled the world’s healthcare systems during the past two years (and appears to be hospitalizing an increasing number of patients again ( revealed a marked demand for repurposing existing drugs for unanticipated treatments, particularly prior to the provisional development of various targeted vaccines to combat the novel coronavirus ( Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the signing of two agreements with Atlanta-based BevNology LLC. According to the update, the first manufacturing operating agreement expands production capabilities for Lexaria’s own growing list of business-to-business (“B2B”) clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands. A new, state-of-the-art processing facility custom-built by BevNology is operational that increases and broadens production capacity and is currently serving Lexaria’s corporate clients. The second commercial license agreement empowers BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (“CBD”) under BevNology and partnered brands. “These agreements build on a long-standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” said Chris Bunka, CEO of Lexaria. “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.” To view the full press release, visit

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.77, up 18.8841%, on 154,823 volume. The average volume for the last 3 months is 154,823 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has extended the maturity of a senior secured convertible note of $28 million, originally due in July 2022, by two years. According to the update, the company originally entered into a secured convertible promissory note on July 23, 2020, with DBI Lease Buyback Servicing LLC, an affiliate of Drawbridge Investments LLC. An existing Mullen shareholder, Esousa Holdings LLC, has acquired the note from Drawbridge and entered into an agreement with Mullen to extend the note’s maturity date. Originally scheduled to mature on July 28, 2022, the note is now extended to July 2024. “This note extension with Esousa is important for us, as it preserves our cash flow at a time when the economy appears to be hitting some headwinds, and it provides the company with a strengthened cash position, allowing us to execute on our EV plans,” said David Michery, CEO and chairman of Mullen Automotive. To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $1.52, up 15.1515%, on 102,353,513 volume. The average volume for the last 3 months is 102.354M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, congratulates Gustavo Petro and the Humane Colombia Party on their victory in Sunday’s presidential runoff election in Colombia. “We would like to congratulate President-Elect Gustavo Petro on his victory, and we look forward to working with the new government to continue Colombia’s progressive momentum in the global cannabis industry,” said Luis Merchan, Flora’s chairman and CEO. “We are encouraged by President-Elect Petro’s stance on seeing Colombia become a leader in the legal cannabis industry, and we are hopeful for progressive legislation that will allow Colombia to create a safe environment for cannabis consumption domestically - potentially leading to a recreational market in the country - while also proving Colombia has all the environmental and labor conditions necessary to be a global cannabis powerhouse.” To view the full press release, visit

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $0.76, up 2.6334%, on 755,344 volume. The average volume for the last 3 months is 755,344 and the stock's 52-week low/high is $0.61/$21.45.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

New research from the Center for Healthcare Policy and Research at UC Davis has found that dose-reduction programs meant to taper patients off opioids and reduce opioid overdoses can increase the risk of mental health risks and patient overdose in the long term. In the study findings, which were published in “JAMA Network Open,” the researchers noted that patients on higher doses of opioid therapy experienced remarkably higher rates of mental-health crises and overdose in the second year after their doses were tapered down by at least 15%. Opioid tapering is meant to steadily wean patients off opioids over a period of weeks without aggravating some of the side effects associated with the continued use of opioids. Firms such as Silo Pharma Inc. (OTCQB: SILO) are focused on finding novel remedies to treat a variety of neurological conditions, and addiction ranks high among the mental-health issues requiring a paradigm shift in their management.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Tuesday's trading session at $0.131, up 0.614439%, on 20,380 volume. The average volume for the last 3 months is 20,380 and the stock's 52-week low/high is $0.101101/$0.2979.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Correlate Infrastructure Partners (OTCQB: CIPI) is a technology-enabled energy optimization and clean energy solutions provider for the U.S. commercial real estate industry. The company today announced the launch of the Correlate Portfolio Health Program with Abundant IoT, dedicated to co-developing a revenue generation program for commercial real estate owners. A portfolio-scale real estate platform, Correlate Infrastructure Partners reduces friction between property owners and service providers to improve net operating income while meeting environmental, social and governance (“ESG”) goals. Abundant IoT is a global technology aggregation services provider focused on IoT and energy services. “The path to full decarbonization will take ambition and intentional execution,” said Todd Michaels, CEO and president of Correlate Infrastructure Partners. “By teaming up with industry innovators and experts, we can guide commercial real estate owners in creating new revenue and rent opportunities from their existing energy assets.” To view the full press release, visit

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Tuesday's trading session at $1.1, even for the day. The average volume for the last 3 months is 250 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX) announced that GrowPods – transportable modular hydroponic farms - can help reduce the global lettuce shortage. The crisis began in 2020 when, according to Growing Produce, California lettuce cultivators faced hotter-than-average temperatures and crop diseases that led to a shortage of iceberg and romaine lettuce. The conditions bled into 2021, with Mintec indicating that lettuce increased in price 67% from the previous year due to low supplies. “Almost all plants grow faster hydroponically than they do in soil-based farming methods,” the publication reported. “This is because the plant’s light, nutrition and water are all under your complete control.” Iceberg lettuce can be harvested in just six to eight weeks, and romaine and butterhead as quickly as three to four weeks. “In general, most hydroponic leafy greens offer 11-13 harvests per year.” To view the full press release, visit

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.95, even for the day, on 222 volume. The average volume for the last 3 months is 222 and the stock's 52-week low/high is $0.54/$3.50.

Recent News

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group (NASDAQ: GMGI), a gaming technology company, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. GMGI’s CEO Brian Goodman joined the latest episode to discuss Golden Matrix’s business model, which includes both business-to-business (“B2B”) and business-to-consumer (“B2C”) operations. “Our core business is B2B. We build gaming systems and provide gaming content to licensed online gaming operators,” Goodman said. “We do this in a number of ways. We can either provide the modules – marketing modules, customer retention, customer acquisition – or we can provide a full turnkey solution. In that way, we assist people operating in a brick-and-mortar environment to transition or add to their business by going online. That’s our expertise. Whilst we have traditionally focused on the Asia-Pacific region, we are now expanding into other global jurisdictions.” To view the full press release, visit

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Tuesday's trading session at $4.7, off by 2.8926%, on 24,679 volume. The average volume for the last 3 months is 24,578 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Precision medicine is a relatively new field in medical technology that has allowed doctors to peer even deeper into the human body, thus broadening the horizons of medical treatments significantly. This groundbreaking technology is now being paired with psychedelics to boost psychedelic research and development.  At the moment, however, most psychedelic research is centered on how these substances target and affect the serotonin 2A receptor in the brain. This receptor is associated with neuropsychiatric disorders and mental health conditions such as post-traumatic stress disorder (PTSD) and chronic depression, and the receptor is often targeted during the treatment of such conditions. All this research adds onto what early entrants such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are doing to advance their drug-development programs. Patients and the society in general will be the net beneficiary once all these efforts yield approved medicines.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.5497, off by 3.6459%, on 709,235 volume. The average volume for the last 3 months is 705,746 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • Odyssey Group International Inc. is a Nevada based medical company developing a variety of drug and technology assets to treat unmet clinical needs
  • Odyssey CEO Michael Redmond recently appeared on Bloomberg TV’s The RedChip Money Report(R) to discuss the development pipeline for three of the company’s four products and pending clinical testing
  • Odyssey’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats, patients dealing with a rare neurodegenerative disorder and patients needing treatment for brain concussion injuries
  • The drug-device combination for treating concussions is advancing in a Phase 1 clinical human trial that is currently enrolling 48 patients

Sixty-five years after retired business and senior finance executive Bob Valentine received life-saving care in Children’s Hospital of Buffalo’s neonatal intensive care unit (“NICU”) to treat respiratory distress syndrome he experienced as a newborn, Valentine made a Valentine’s Day donation of $500,000 this year to the hospital’s foundation, which established a fund to help families experiencing a similar journey ( Valentine’s expression of gratitude for what was then revolutionary medical care is by no means unique in the annals of emergency treatments that have helped patients overcome traumatic developments and go on to pursue their lives. A Long John Silver’s business executive recently gifted $1 million to a university’s research fellowship after cardiothoracic surgery there resolved heart problems that endangered his life ( And sometimes the expressions of gratitude have a more intangible value, such as when a family publicly praised a police officer’s CPR efforts that saved a choking child, who wrote the officer a thank you card ( Odyssey Health (OTC: ODYY) is dedicated to advancing lifesaving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. 

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Tuesday's trading session at $0.235, off by 9.0909%, on 21,286 volume. The average volume for the last 3 months is 21,286 and the stock's 52-week low/high is $0.11/$0.7998.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

  • Eat Well completed the acquisition of Belle Pulses, Sapientia, and Amara Organic Foods within the 2021 financial year, producing a 1,082% asset growth over that period
  • In addition to raising over $33 million of debt, the company also bolstered its Board of Directors and advisory board
  • Eat Well is confident that with the foundation laid down so far, it’s portfolio companies will achieve revenues of between $90 million and $110 million in 2022, with bottom-line profitability and combined investments growing throughout the year

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) just released its financial reports for the fourth quarter and the entire year of 2021. When making the announcement, Marc Aneed, the company’s Director, President, and Chief Executive Officer (“CEO”), noted that over the course of the 2021 financial year, the company laid a strong foundation, positioning its portfolio companies to capture global pulse demand, and satisfy consumer needs (

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.


On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Tuesday's trading session at $0.1652, off by 3.5047%, on 19,170 volume. The average volume for the last 3 months is 19,170 and the stock's 52-week low/high is $0.1512/$1.00.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Marijuana is rarely on the table whenever discussions of climate change are underway. However, as the world grapples with the effects of decades of greenhouse emissions and runaway climate change, cannabis growers will find that they have to adapt. It is essentially the same issue that has disrupted agricultural-based industries such as wine: shifting weather patterns coupled with climate change are making regions that have previously the perfect conditions for cultivating inhospitable. In the next couple of years, marijuana growers in the country may have to change where and how they grow cannabis if they wish to remain competitive. She is also considering shorter-term genetics such as autoflowers. Cannabis is an extremely adaptable plant that can thrive in any location, Fortier declares. Collaboration between farmers and breeders will help them develop strains and cultivation methods that can withstand shifting weather patterns and climate change so that sector actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) can continue to meet the needs of their clients without compromising quality or raising prices excessively in a bid to recover the extra costs brought by climate change.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Tuesday's trading session at $0.011505, off by 8.6905%, on 2,810,581 volume. The average volume for the last 3 months is 2.711M and the stock's 52-week low/high is $0.0103/$0.08.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.